Literature DB >> 28833384

Primary hyperparathyroidism in Chinese children and adolescents: A single-centre experience at Peking Union Medical College Hospital.

Wenbo Wang1, Jing Kong1, Min Nie1, Yan Jiang1, Mei Li1, Weibo Xia1, Xunwu Meng1, Xiaoping Xing1, Ou Wang1.   

Abstract

OBJECTIVE: Primary hyperparathyroidism (PHPT) in children is thought to be extremely rare. Our study aimed to summarize the clinical characteristics and the molecular genetics in patients with paediatric PHPT in China.
DESIGN: Retrospective observational study.
METHODS: A total of 59 paediatric PHPT patients (onset age <18 years) admitted to Peking Union Medical College Hospital from 1975 to 2015 were retrospectively identified. A group of 118 adult PHPT patients who presented during the same period were selected for comparing clinical characteristics between the two groups. Germline mutation analyses of the MEN1, CDC73, RET, CDKN1B and CaSR genes were performed in 24 patients.
RESULTS: Only one paediatric patient (1.7%) with PHPT was asymptomatic. Bone involvement, urolithiasis, acute pancreatitis and hypercalcaemic crisis were present in 86.4%, 39.0%, 6.8% and 10.2% of cases, respectively. Paediatric PHPT presented more commonly with rickets/osteomalacia compared to adult PHPT. Fifty-seven paediatric patients underwent surgery. Adenoma, hyperplasia, atypical adenoma and carcinoma occurred in 80.7%, 10.5%, 7.0% and 1.8% of cases, respectively. Of the 24 paediatric patients screened for genetic mutations, two patients were found to carry MEN1 mutations and six were found to carry CDC73 mutations. The mutation rate was 22.2% (4/18) in sporadic patients.
CONCLUSION: Unlike adults with PHPT, most paediatric PHPT were symptomatic. Rickets/osteomalacia was more common in paediatric patients than in their adult counterparts. Paediatric PHPT patients can be treated successfully with surgical intervention. Genetic screening of the MEN1 and CDC73 genes for mutations should be recommended in paediatric patients due to a relatively high mutation rate.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  genetic; paediatric; primary hyperparathyroidism; rickets

Mesh:

Substances:

Year:  2017        PMID: 28833384     DOI: 10.1111/cen.13453

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

Review 1.  Use of calcimimetics in children with normal kidney function.

Authors:  Judith Sebestyen VanSickle; Tarak Srivastava; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2018-03-19       Impact factor: 3.714

2.  "Primary Hyperparathyroidism (PHPT) in Children: Two Case Reports and Review of the Literature".

Authors:  Gerdi Tuli; Jessica Munarin; Daniele Tessaris; Raffaele Buganza; Patrizia Matarazzo; Luisa De Sanctis
Journal:  Case Rep Endocrinol       Date:  2021-04-13

3.  Hypercalcemic crisis caused by primary hyperparathyroidism in a 11-year-old boy: a rare case report and review of the literature.

Authors:  Shigeki Hayashi; Takaaki Oba; Kanami Ichikawa; Chizuko Nakamura; Yosuke Hara; Toshiharu Kanai; Yoshinori Sato; Takeshi Uehara; Ken-Ichi Ito
Journal:  Gland Surg       Date:  2022-07

Review 4.  Multiple Endocrine Neoplasia Type 1: Latest Insights.

Authors:  Maria Luisa Brandi; Sunita K Agarwal; Nancy D Perrier; Kate E Lines; Gerlof D Valk; Rajesh V Thakker
Journal:  Endocr Rev       Date:  2021-03-15       Impact factor: 19.871

5.  When Parathyroidectomy Should Be Indicated or Postponed in Adolescents With MEN1-Related Primary Hyperparathyroidism.

Authors:  Francesca Marini; Francesca Giusti; Francesco Tonelli; Maria Luisa Brandi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-05       Impact factor: 5.555

6.  Case report: incidental parathyroid adenoma in a Chinese diabetic patient with hypercalcemia and normal parathyroid hormone levels.

Authors:  Can Pang; Youben Fan; Huizheng Zhang; Haoyong Yu; Bomin Guo; Jie Kang; Xianzhao Deng; Yuqian Bao
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.